IDEAYA Biosciences (NASDAQ:IDYA) Given New $38.00 Price Target at Royal Bank Of Canada

IDEAYA Biosciences (NASDAQ:IDYA) had its target price hoisted by Royal Bank Of Canada from $36.00 to $38.00 in a research note published on Tuesday morning, Marketbeat reports. The firm currently has an outperform rating on the stock.

Several other analysts also recently commented on IDYA. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a report on Tuesday. Stephens reiterated an “overweight” rating and set a $45.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday. Barclays began coverage on IDEAYA Biosciences in a research report on Thursday, September 4th. They set an “overweight” rating and a $40.00 target price for the company. The Goldman Sachs Group raised shares of IDEAYA Biosciences to a “hold” rating and set a $25.00 target price on the stock in a research note on Thursday, July 10th. Finally, TD Cowen assumed coverage on shares of IDEAYA Biosciences in a research note on Tuesday, July 22nd. They set a “buy” rating on the stock. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.75.

IDEAYA Biosciences Trading Up 0.9%

IDYA opened at $24.93 on Tuesday. The company’s fifty day moving average price is $23.89 and its two-hundred day moving average price is $20.72. IDEAYA Biosciences has a 1-year low of $13.45 and a 1-year high of $37.80. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -6.58 and a beta of 0.12.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The business had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $3.48 million. During the same quarter last year, the firm posted ($0.68) EPS. The company’s revenue was up NaN% on a year-over-year basis. As a group, equities analysts forecast that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

Institutional Trading of IDEAYA Biosciences

Several large investors have recently added to or reduced their stakes in IDYA. Oppenheimer Asset Management Inc. boosted its holdings in shares of IDEAYA Biosciences by 33.2% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company’s stock valued at $189,000 after buying an additional 2,884 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of IDEAYA Biosciences by 9.6% during the 1st quarter. Rhumbline Advisers now owns 124,437 shares of the company’s stock valued at $2,038,000 after buying an additional 10,876 shares in the last quarter. Palumbo Wealth Management LLC boosted its holdings in shares of IDEAYA Biosciences by 65.8% during the 1st quarter. Palumbo Wealth Management LLC now owns 22,402 shares of the company’s stock valued at $367,000 after buying an additional 8,893 shares in the last quarter. Swiss National Bank boosted its holdings in shares of IDEAYA Biosciences by 0.8% during the 1st quarter. Swiss National Bank now owns 150,800 shares of the company’s stock valued at $2,470,000 after buying an additional 1,200 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in IDEAYA Biosciences by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company’s stock worth $83,417,000 after purchasing an additional 14,535 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.